Loading
8 slides generated from the cancer page, with a quiz from the open benchmark and speaker notes that cite the sources. Arrow keys move between slides; Print gives one slide per page.
Low-risk neuroblastoma is the form found in infants and young children whose tumour has not spread beyond its site or, in the special stage MS pattern, has spread only to the liver, skin and a little marrow. Many of these tumours shrink and disappear on their own, so treatment is surgery, or simply watching, and almost every child survives.
Neuroblastoma arises from sympathetic nervous system precursors, most often in the adrenal, and the same histology spans one of the widest ranges of behaviour in oncology. The International Neuroblastoma Risk Group (INRG) classification of 2009 assigns pretreatment risk from image-defined risk factors (stage L1 or L2), metastatic pattern (M or MS), age, MYCN status, 11q aberration, ploidy and histology. Very low and low risk covers L1 tumours without MYCN amplification at any age, L2 tumours in infants without unfavourable biology, and stage MS in infants under 18 months: metastases confined to skin, liver and less than 10 percent of marrow, which regress spontaneously. Screening programmes in Japan, Quebec and Germany in the 1980s and 1990s found many more infant tumours than ever came to clinical attention and did not reduce deaths, proof that a large fraction of infant neuroblastoma regresses unseen.
The Children's Oncology Group trial P9641 treated children with low-risk disease by surgery alone, reserving chemotherapy for symptoms or incomplete resection with unfavourable biology: five-year event-free survival was 89 percent and overall survival 97 percent, with almost every child who relapsed rescued. The German NB97 trial observed infants with localised unresected tumours and saw spontaneous regression in around half. COG ANBL1232 then went further, observing small adrenal masses in infants under six months without biopsy, and expectant observation of L2 tumours in children under 18 months with favourable biology; the SIOPEN LINES study runs the same strategy in Europe. Stage MS infants are watched unless a rapidly enlarging liver threatens breathing or the kidneys, when a short course of carboplatin and etoposide or low-dose cyclophosphamide is given.
| Setting | Approach | Guideline |
|---|---|---|
| L1 tumours and small adrenal masses in infants | Observation with serial ultrasound and urinary catecholamines, or surgical resection; no chemotherapy. | not mapped |
| L2 tumours in infants with favourable biology | Expectant observation or surgery; short carboplatin and etoposide or cyclophosphamide only for symptoms or threat to organs. | not mapped |
| Stage MS | Observation; carboplatin and etoposide or low-dose cyclophosphamide for a rapidly enlarging liver or respiratory compromise. | not mapped |
| Follow-up | Ultrasound and urinary catecholamines, tapering over years; late-effects follow-up for the few who received chemotherapy. | not mapped |